• Special Issue Topic

    Endocrine Resistant Breast Cancer

    Submission Deadline: October 31, 2021

    Guest Editors

    Dr. Simon Langdon E-Mail

    Reader, School of Medicine, University of Edinburgh, Edinburgh, UK

    Research Keywords: ovarian cancer; breast cancer; estrogen signaling; HER signaling; DNA repair

    Dr. Valerie Speirs E-Mail

    Professor and Chair in Molecular Oncology, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK

    Research Keywords: oestrogen receptor biology; endocrine resistant breast cancer; male breast cancer; in vitro models; biomarker

    About the Special Issue

    The majority of breast cancers are estrogen receptor alpha (ERa) positive and most will initially respond to endocrine therapy. Current therapies to treat ERa-positive disease include aromatase inhibitors, selective estrogen receptor modulators (SERMs) and selective estrogen down-regulators (SERDs). However, resistance to these treatments will develop in many cancers and can be present either at the outset (de novo resistance) or develop on treatment (acquired resistance). Experimental and clinical investigations have demonstrated multiple mechanisms that can give rise to resistance and a range of therapeutic agents such as CDK4/6 inhibitors and other signalling inhibitors have been developed to circumvent these. Resistance mechanisms include changes in ER status (e.g. loss and mutation) and the involvement of compensatory pathways bypassing the dependence on estrogen activation particularly growth factor activation.

    In this issue, we welcome Reviews and Original Articles encompassing experimental laboratory research studies of endocrine resistance through to clinical investigations in breast cancer.

    Keywords: Breast cancer; resistance; endocrine; estrogen

    Published Articles

    Open Access
    Endocrine therapy resistance: what we know and future directions
    Endocrine resistance is a major hurdle in the treatment of estrogen receptor (ER)-positive breast cancer. When abnormally regulated, molecular signals responsible for cellular proliferation, as well [...] Read more.
    David Musheyev, Anya Alayev
    Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:480–496
    DOI: https://doi.org/10.37349/etat.2022.00096
    Open Access
    Exploring new pathways in endocrine-resistant breast cancer
    The most common breast cancer (BC) subtypes are hormone-dependent, being either estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), or both, and altogether comprise the luminal subtype. Th [...] Read more.
    Inês Soares de Pinho ... Luís Costa
    Published: June 20, 2022 Explor Target Antitumor Ther. 2022;3:337–361
    DOI: https://doi.org/10.37349/etat.2022.00086
    Open Access
    In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy
    The development of endocrine resistance is a common reason for the failure of endocrine therapies in hormone receptor-positive breast cancer. This review provides an overview of the different types  [...] Read more.
    Gary J. Cheng ... Dean C. Singleton
    Published: June 01, 2022 Explor Target Antitumor Ther. 2022;3:297–320
    DOI: https://doi.org/10.37349/etat.2022.00084
    Open Access
    Endocrine resistant breast cancer: brain metastasis
    Endocrine resistant breast cancer metastasis continues to serve as a significant clinical challenge with high morbidity and mortality for patients. As the number of breast cancer cases continues to  [...] Read more.
    Matthew Willman ... Brandon Lucke-Wold
    Published: April 26, 2022 Explor Target Antitumor Ther. 2022;3:240–251
    DOI: https://doi.org/10.37349/etat.2022.00081
    Open Access
    Original Article
    The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer
    Aim: Zinc is a key secondary messenger that can regulate multiple signalling pathways within cancer cells, thus its levels need to be strictly controlled. The Zrt, Irt-like protein (ZIP, SLC39A)  [...] Read more.
    Samuel Jones ... Kathryn M. Taylor
    Published: April 26, 2022 Explor Target Antitumor Ther. 2022;3:224–239
    DOI: https://doi.org/10.37349/etat.2022.00080
    Open Access
    Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
    The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a [...] Read more.
    Aglaia Skolariki ... Simon Lord
    Published: April 24, 2022 Explor Target Antitumor Ther. 2022;3:172–199
    DOI: https://doi.org/10.37349/etat.2022.00078
    Open Access
    Original Article
    Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model
    Aim: A model of progressively endocrine-resistant breast cancer was investigated to identify changes that can occur in signaling pathways after endocrine manipulation. Methods: The MCF7 breas [...] Read more.
    Kate M. Moore ... Simon P. Langdon
    Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:97–116
    DOI: https://doi.org/10.37349/etat.2022.00074
    Times Cited: 0
    Open Access
    Interface between obesity with dysfunctional metabolism and inflammation, and the triple-negative breast cancer in African American women
    Obesity has dramatically increased over the past fifty years. In the last decade, it has been noted that augmented body mass, metabolic abnormalities, and the relevant “obese” [...] Read more.
    Katarzyna Rygiel
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:602–616
    DOI: https://doi.org/10.37349/etat.2021.00066
    Open Access
    Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
    Adjuvant hormonal therapy is one of the most important treatments of hormone-receptor-positive breast cancer and includes selective estrogen receptor modulators, aromatase inhibitors, and luteinizin [...] Read more.
    Alfredo Rossi ... Marta Carlesimo
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:490–495
    DOI: https://doi.org/10.37349/etat.2021.00059
    Open Access
    Role of estrogen receptor coregulators in endocrine resistant breast cancer
    Breast cancer (BC) is the most ubiquitous cancer in women. Approximately 70–80% of BC diagnoses are positive for estrogen receptor (ER) alpha (ERα). The steroid ho [...] Read more.
    Kristin A. Altwegg, Ratna K. Vadlamudi
    Published: August 30, 2021 Explor Target Antitumor Ther. 2021;2:385–400
    DOI: https://doi.org/10.37349/etat.2021.00052